Everything below concerns GHRH receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Before the infusions, participants received oral corticosteroids, histamine receptor blockers, and acetaminophen to reduce the risk of infusion-related reactions, which by themselves will cause several side effects.
Turin is home to one of Italy's oldest universities, the University of Turin, including its affiliated Collegio Carlo Alberto, which ranks among the best universities in the country. Another established university in the city is the Polytechnic University of Turin, ranking among Top 50 universities in the world and #1 in Italy in the fields of engineering, technology and computer science ("Academic Ranking of World Universities" published by Shanghai Jiao Tong University). Turin also hosts the United Nations System Staff College, the European Training Foundation, and a campus of the ESCP business school, ranked among the 10 best business schools in Europe. Moreover, the city hosts three small English language post-secondary institutions: St. John International University, International University College of Turin, and the Turin School of Development. In 2025, Turin becomes the first city in Italy with a plan to combat Islamophobia.
From 1951 Sanger was a member of the external staff of the Medical Research Council and when they opened the Laboratory of Molecular Biology in 1962, he moved from his laboratories in the Biochemistry Department of the university to the top floor of the new building. He became head of the Protein Chemistry division. Prior to his move, Sanger began exploring the possibility of sequencing RNA molecules and began developing methods for separating ribonucleotide fragments generated with specific nucleases. This work he did while trying to refine the sequencing techniques he had developed during his work on insulin. The key challenge in the work was finding a pure piece of RNA to sequence. In the course of the work he discovered in 1964, with Kjeld Marcker, the formylmethionine tRNA which initiates protein synthesis in bacteria. He was beaten in the race to be the first to sequence a tRNA molecule by a group led by Robert Holley from Cornell University, who published the sequence of the 77 ribonucleotides of alanine tRNA from Saccharomyces cerevisiae in 1965. By 1967 Sanger's group had determined the nucleotide sequence of the 5S ribosomal RNA from Escherichia coli, a small RNA of 120 nucleotides.
== Cost == Monoclonal antibodies are more expensive to manufacture than small molecules due to the complex processes involved and the general size of the molecules, all in addition to the enormous research and development costs involved in bringing a new chemical entity to patients. They are priced to enable manufacturers to recoup the typically large investment costs, and where there are no price controls, such as the United States, prices can be higher if they provide great value. Seven University of Pittsburgh researchers concluded, "The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states", comparing them on a per patient basis, to those for cardiovascular or metabolic disorders, immunology, infectious diseases, allergy, and ophthalmology.
Microfilaments at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Microfilament+proteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Microfilament" at Dorland's Medical Dictionary
Sources: en.wikipedia.org
Some forms of fabrication tested in outer space are fused deposition printing, which employs 3D printing methods to print using layer-by-layer filament extrusions, semi-solid and direct powder extrusion, effective for bioprinting applications and can be leveraged to process materials found in outer space (silica, magnesium silicate, and calcium phosphate), and photopolymerization, which uses light to print a resin in a layer-by-layer mechanism. These methods are not only used for drug manufacturing but also for biomaterials or medical devices that can load drugs. Finally, methods are used to conduct quality assurance, such as gas chromatography, mass spectrometry, infrared spectroscopy, nuclear magnetic resonance spectroscopy, and other such techniques to identify potential toxins in drug formulations. Advances in handheld, portable, and component miniaturization have developed spectroscopy methods to be more accessible for outer space applications. For example, Raman spectroscopy is a handheld device that can measure drug degradation and drug parameters and efficacy.
== External links == Vincent du Vigneaud on Nobelprize.org including the Nobel Lecture, December 12, 1955 A Trail of Sulfa Research: From Insulin to Oxytocin https://weill.cornell.edu/archives/pdf/personal_aids/DuVigneaud.pdf
=== Adhesion to zirconia === Tensile bond strength to zirconia of ethanol solutions that contains MDP were measured. MDP showed high bond strengths to zirconia. Tensile bond strengths of MDP containing resin composites to zirconia ceramic were statistically significantly higher when compared with the bond strength of the conventional Bis-GMA resin composite which contains no adhesive monomer. The mechanisms of coordination between MDP and zirconium oxide were demonstrated by using 1H and 31P magic angle spinning nuclear magnetic resonance (NMR) and two dimensional 1H → 31P heteronuclear correlation NMR. The spectra indicated three possible models as mechanisms of interaction of MDP with zirconia.
"Patent Pending". FBI: Most Wanted. Season 4. Episode 6. 15 November 2022. CBS. "Via Negativa". The X-Files. Season 8. Episode 7. 17 December 2000. Fox Broadcasting Company. "Getting Off". CSI: Crime Scene Investigation. Season 4. Episode 16. 26 February 2004. CBS. "Users". Law & Order: Special Victims Unit. Season 11. Episode 7. 4 November 2009. NBC. "Echoes". Nikita. Season 1. Episode 16. 24 February 2011. The CW Television Network. "One Last Time". Homeland (TV series). Season 3. Episode 9. 24 November 2013. Showtime. "Bon Voyage". Graceland (TV series). Season 3. Episode 7. 6 August 2015. USA Network.
Sources: en.wikipedia.org
=== Nucleotides === For polynucleic acids (DNA/RNA), the monomers are nucleotides, each of which is made of a pentose sugar, a nitrogenous base and a phosphate group. Nucleotide monomers are found in the cell nucleus. Four types of nucleotide monomers are precursors to DNA and four different nucleotide monomers are precursors to RNA.
=== Phytochemicals === At least twenty-seven phytochemicals have been detected in G. globosa including six phenolic acid derivatives and fifteen specific flavonoids. The most abundant phenolic compounds present are flavonoids. A major phenol was found to be kaempferol 3-O-rutinoside based on chromatographic and mass spectrometry techniques. Gomphrenol derivatives also contribute to phenolic content. Other flavanols include quercetin, kaempferol, and isorhamnetin derivatives.
=== Mid-cycle === The absence of GnSAF lowers the threshold for GnRH pulse frequency and amplitude required to stimulate the anterior pituitary to secrete LH. Concurrently, GnRH pulse frequency and amplitude increases, which allows LH secretion significantly higher than basal levels. The LH secretion most noticeable as a LH surge lasting 48 to 72 hours in the middle of the ovarian cycle. Meiosis in the dominant follicle resumes and follicle ruptures shortly after the LH surge. Ovulation can only occur if GnSAF is absent and the mid-cycle LH surge occurs.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.